- Report
- January 2026
- 224 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 374 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 285 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 294 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 419 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 577 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 285 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 108 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 214 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 166 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 245 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 282 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 382 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 462 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 375 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 360 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 183 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 192 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 196 Pages
Global
From €5195EUR$5,850USD£4,511GBP
- Report
- January 2026
- 196 Pages
Global
From €5195EUR$5,850USD£4,511GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more